TransMedics Group(NASDAQ) TMDX

TransMedics Group, Inc. NASDAQ:TMDX helps doctors keep donor organs alive during transport. This technology replaces the standard method of keeping organs on ice. It helps more patients receive life-saving transplants.

From Machines to Managed Services

• OCS Liver: Portable system designed to maintain donor livers in near-physiological conditions using specialized perfusion technology.
• OCS Heart: Device used for the extracorporeal perfusion and maintenance of donor hearts outside the human body.
• OCS Lung: Module used to preserve and monitor donor lungs for double-lung transplants.
• National OCS Program: Solution providing outsourced organ procurement, clinical management, and transplant logistics.
• Transplant Logistics: Services including aviation and ground transportation to coordinate the delivery of donor organs.

Scaling the National Logistics Network

• Obtained Pre-Market Approval from the FDA for heart, lung, and liver perfusion systems.
• Purchased transplant aircraft to support aviation transportation for the National OCS Program.
• Commenced a finance lease for a new global headquarters in Somerville, Massachusetts, in Jan. 2026.
• Secured CE mark recertification for heart and lung systems under European Union regulations in Sept. 2022.
• Obtained a Class II Medical Device License for the OCS Liver system from Health Canada in Oct. 2023.

One of a Kind Technology

TransMedics operates the only portable, multi-organ, warm perfusion technology platform with FDA approval. The company integrates its proprietary technology with a national logistics network to improve organ procurement efficiency across the United States.

Checking the Vital Signs

• Total revenue was $189.9 million for the three-month period ended June 30, 2026.
• Revenue from United States customers reached $350.6 million for the six-month period ended June 30, 2026, up $59.8 million year over year.
• Net income was $22.0 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents reached $472.7 million as of June 30, 2026.
• Market capitalization was $2.8 billion with a P/E ratio of 39.5 based on recent market data.

Bottom Line

TransMedics has evolved from a medical device developer into an integrated provider of transplant technology and logistics. This transition from static storage to a managed service model aims to increase the supply of transplantable organs.